Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine for perioperative mood disorders in malignant tumor patients undergoing Haifu therapy
ChiCTR2100053841Phase 4Recruiting
- Sponsor
- The 2nd Affiliated Hospital of Chongqing Medical University
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of esketamine in affective disorder, major depressive disorder (MDD) and anxiety disorder (2 arms), sponsored by The 2nd Affiliated Hospital of Chongqing Medical University. Primary endpoints: Hamilton Depression Scale Score and Hamilton Anxiety Scale Score. Started Dec 2021; status: recruiting.
02
Drugs
esketamine
03
Conditions
affective disordermajor depressive disorder (MDD)anxiety disorder
Beyond the preview
Go deeper on ChiCTR2100053841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053841.